Landmark First Research Test Kit for Systemic Sclerosis Launched
|
By LabMedica International staff writers Posted on 24 Aug 2014 |
|
A novel combination of biomarkers has been developed into a test kit to facilitate diagnostics research of systemic sclerosis specifically and complex autoimmune diseases in general.
Protagen AG (Dortmund, Germany), dedicated to development of novel diagnostic and companion diagnostic tests to provide better and earlier diagnosis of severe autoimmune diseases, has launched its first ELISA, currently research-use-only, test kit – the ADx SSc Multilisa – for Systemic Sclerosis (SSc; also termed scleroderma), a complex, multi-organ rheumatic disease in which autoimmune dysregulation leads to a complex pattern of organ-specific complications associated with high mortality and morbidity. Protagen developed the new assay to synergistically combine 2 proprietary, novel disease markers with 2 standard diagnostic markers to support medical research in autoimmune diseases.
Stefan Müllner, CEO of Protagen AG, said, “Based on our long track record in the discovery and validation of autoantigen biomarkers using the proprietary SeroTag technology, our development pipeline is built on a strong patent portfolio and designed to support clinical research, targeted therapy, and the continuous delivery of novel diagnostic products.” The 3 most frequently observed autoantibodies are only present in about 60%-70% of SSc patients: anti-topoisomerase I (anti-Scl70), anti-centromere (ACA), and anti-RNA polymerase III (ARA). Protagen has focused on the identification of a new class of biomarkers for SSC to augment current diagnostic tools. Extensive research via the company´s SeroTag platform revealed 2 novel SSc-associated antigens: KDM6B and BICD2. The ADx SSc Multilisa kit enables simultaneous qualitative in vitro detection of antibodies against domains of Scl-70 (topoisomerase I),CENP-B, KDM6B, and BICD2, within human serum or plasma.
SSc is one of a number of complex autoimmune diseases that Protagen is working to address with tools to help clinical researchers identify markers for improved diagnostic and this new introduction represents a key milestone in the company’s pipeline. Mr. Müllner added, “This underscores our strategy to provide new, improved solutions and product options in autoimmune indications on a continuous basis, enable better therapeutic decision making, and improve the diagnostic process for clinicians and, importantly, patients.”
ADx SSc Multilisa is currently intended for use as a scientific research-use-only (RUO) tool, and is in further clinical testing to build a diagnostic claim for early disease detection or stratification from August 2014.
Related Links:
Protagen
 assay.jpg)
Protagen AG (Dortmund, Germany), dedicated to development of novel diagnostic and companion diagnostic tests to provide better and earlier diagnosis of severe autoimmune diseases, has launched its first ELISA, currently research-use-only, test kit – the ADx SSc Multilisa – for Systemic Sclerosis (SSc; also termed scleroderma), a complex, multi-organ rheumatic disease in which autoimmune dysregulation leads to a complex pattern of organ-specific complications associated with high mortality and morbidity. Protagen developed the new assay to synergistically combine 2 proprietary, novel disease markers with 2 standard diagnostic markers to support medical research in autoimmune diseases.
Stefan Müllner, CEO of Protagen AG, said, “Based on our long track record in the discovery and validation of autoantigen biomarkers using the proprietary SeroTag technology, our development pipeline is built on a strong patent portfolio and designed to support clinical research, targeted therapy, and the continuous delivery of novel diagnostic products.” The 3 most frequently observed autoantibodies are only present in about 60%-70% of SSc patients: anti-topoisomerase I (anti-Scl70), anti-centromere (ACA), and anti-RNA polymerase III (ARA). Protagen has focused on the identification of a new class of biomarkers for SSC to augment current diagnostic tools. Extensive research via the company´s SeroTag platform revealed 2 novel SSc-associated antigens: KDM6B and BICD2. The ADx SSc Multilisa kit enables simultaneous qualitative in vitro detection of antibodies against domains of Scl-70 (topoisomerase I),CENP-B, KDM6B, and BICD2, within human serum or plasma.
SSc is one of a number of complex autoimmune diseases that Protagen is working to address with tools to help clinical researchers identify markers for improved diagnostic and this new introduction represents a key milestone in the company’s pipeline. Mr. Müllner added, “This underscores our strategy to provide new, improved solutions and product options in autoimmune indications on a continuous basis, enable better therapeutic decision making, and improve the diagnostic process for clinicians and, importantly, patients.”
ADx SSc Multilisa is currently intended for use as a scientific research-use-only (RUO) tool, and is in further clinical testing to build a diagnostic claim for early disease detection or stratification from August 2014.
Related Links:
Protagen
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Human Estradiol Assay
Human Estradiol CLIA Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Latest Hematology News
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more
Molecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read more
Hematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Microbiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more
Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Pathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read more
AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
Technology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
Industry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more
